Early blockage of Mycobacterium Tuberculosis Cell-wall Synthesis via EchA\6 Inhibition to Overcome Resistance Strain: Insights from Umbrella Sampling Simulations

Q2 Pharmacology, Toxicology and Pharmaceutics
Noeman Ardalan, Rafee Habib Askandar, Farhad Sharifi, S. Shayan, Helya Mohammadi, Arian Rahimi, Heshw Farhad Mohammed
{"title":"Early blockage of Mycobacterium Tuberculosis Cell-wall Synthesis via EchA\\6 Inhibition to Overcome Resistance Strain: Insights from Umbrella Sampling Simulations","authors":"Noeman Ardalan, Rafee Habib Askandar, Farhad Sharifi, S. Shayan, Helya Mohammadi, Arian Rahimi, Heshw Farhad Mohammed","doi":"10.2174/1573407219666230614163801","DOIUrl":null,"url":null,"abstract":"\n\nTuberculosis (TB) has long been the major infectious cause of mortality, ranking higher than HIV/AIDS as the most common cause of death from a single infectious agent worldwide. The EchA6 target of mycobacteria plays a vital role in synthesizing an important component of the mycobacterial outer membrane. The failure of TB treatment has prompted the investigation of novel anti-tubercular drugs.\n\n\n\nThis study was aimed at blockage of Mycobacterium tuberculosis cell-wall synthesis via EchA6 inhibition to overcome resistance strain.\n\n\n\nOver 3,000,000 compounds and GSK951A (positive control) were investigated as the inhibitors in this study. The GROMACS molecular dynamic package was used to analyze the protein-inhibitor complex's conformational changes under constant temperature and pressure. Also, umbrella sampling (US) was used for free binding energy (∆G) calculation.\n\n\n\nFour compounds were chosen for the docking investigation. According to the MD analysis, the studied inhibitors demonstrated good stability and flexibility. According to ∆G obtained from US, the ∆G of GSK951A, ZINC11815220, ZINC67770050, ZINC55048326, and ZINC89700914 were -6.14 kcal mol-1, -5.25 kcal mol-1, -10.19 kcal mol-1, -8.55 kcal mol-1, and -8.37 kcal mol-1, respectively.\n\n\n\nIn conclusion, ZINC67770050 is recommended for further study in the laboratory. This investigation is an important starting point for discovering anti-tubercular drugs using EchA6 inhibition.\n","PeriodicalId":10772,"journal":{"name":"Current Bioactive Compounds","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Bioactive Compounds","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573407219666230614163801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis (TB) has long been the major infectious cause of mortality, ranking higher than HIV/AIDS as the most common cause of death from a single infectious agent worldwide. The EchA6 target of mycobacteria plays a vital role in synthesizing an important component of the mycobacterial outer membrane. The failure of TB treatment has prompted the investigation of novel anti-tubercular drugs. This study was aimed at blockage of Mycobacterium tuberculosis cell-wall synthesis via EchA6 inhibition to overcome resistance strain. Over 3,000,000 compounds and GSK951A (positive control) were investigated as the inhibitors in this study. The GROMACS molecular dynamic package was used to analyze the protein-inhibitor complex's conformational changes under constant temperature and pressure. Also, umbrella sampling (US) was used for free binding energy (∆G) calculation. Four compounds were chosen for the docking investigation. According to the MD analysis, the studied inhibitors demonstrated good stability and flexibility. According to ∆G obtained from US, the ∆G of GSK951A, ZINC11815220, ZINC67770050, ZINC55048326, and ZINC89700914 were -6.14 kcal mol-1, -5.25 kcal mol-1, -10.19 kcal mol-1, -8.55 kcal mol-1, and -8.37 kcal mol-1, respectively. In conclusion, ZINC67770050 is recommended for further study in the laboratory. This investigation is an important starting point for discovering anti-tubercular drugs using EchA6 inhibition.
通过EchA\6抑制早期阻断结核分枝杆菌细胞壁合成以克服抗性菌株:来自伞形采样模拟的见解
长期以来,结核病一直是造成死亡的主要传染原因,在全球范围内,结核病是单一传染源最常见的死亡原因,其排名高于艾滋病毒/艾滋病。分枝杆菌的EchA6靶标在合成分枝杆菌外膜的重要成分中起着至关重要的作用。结核病治疗的失败促使人们对新型抗结核药物进行了研究。本研究旨在通过抑制EchA6来阻断结核分枝杆菌细胞壁合成,以克服耐药菌株。在本研究中,超过3000000种化合物和GSK951A(阳性对照)被研究为抑制剂。使用GROMACS分子动力学软件包分析蛋白质抑制剂复合物在恒温恒压下的构象变化。此外,伞形采样(US)用于自由结合能(∆G)的计算。选择了四种化合物进行对接研究。根据MD分析,所研究的抑制剂显示出良好的稳定性和灵活性。根据从US获得的∆G,GSK951A、ZINC11815220、ZINC67770050、ZINC55048326和ZINC89700914的∆G分别为-6.14 kcal mol-1、-5.25 kcal mol-2、-10.19 kcal mol-3、-8.55 kcal mol-5和-8.37 kcal mol-4。总之,建议对ZINC67770050进行进一步的实验室研究。这项研究是发现使用EchA6抑制的抗结核药物的重要起点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Bioactive Compounds
Current Bioactive Compounds Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.90
自引率
0.00%
发文量
112
期刊介绍: The journal aims to provide comprehensive review articles on new bioactive compounds with proven activities in various biological screenings and pharmacological models with a special emphasis on stereoeselective synthesis. The aim is to provide a valuable information source of bioactive compounds synthesized or isolated, which can be used for further development of pharmaceuticals by industry and academia. The journal should prove to be essential reading for pharmacologists, natural product chemists and medicinal chemists who wish to be kept informed and up-to-date with the most important developments on new bioactive compounds of natural or synthetic origin, including their stereoeselective synthesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信